

Novitium and Lannett – Recall of ranitidine

- On October 25, 2019, [Novitium Pharma](#) and [Lannett announced](#) the voluntary, consumer-level recall of prescription [ranitidine](#) capsules and prescription [ranitidine](#) syrup due to potential contamination with N-nitrosodimethylamine (NDMA) above levels established by the FDA.
- All quantities and lots of Novitium’s ranitidine capsules are being recalled. Refer to the Lannett press release for a complete list of impacted lots.

Manufacturer	Product Description	NDC#
Novitium	Ranitidine 150 mg capsules, 60 count bottle	70954-001-20
	Ranitidine 150 mg capsules, 500 count bottle	70954-001-40
	Ranitidine 300 mg capsules, 30 count bottle	70954-002-10
	Ranitidine 300 mg capsules, 100 count bottle	70954-002-40
Lannett	Ranitidine 15 mg/mL oral solution, 16 oz. bottle	54838-550-80

- Prescription ranitidine is approved for multiple indications, including treatment and prevention of ulcers of the stomach and intestines and treatment of gastroesophageal reflux disease.
- Other manufacturers, including [Apotex](#), [Perrigo](#) and [Sanofi](#) have recently announced retail level recalls of their OTC ranitidine products. [Dr. Reddy’s](#) recently announced a consumer level recall of prescription ranitidine products.
- In September, [Sandoz](#) issued a consumer level recall of prescription ranitidine products.
- These recalls follow a recent [FDA statement](#) about NDMA impurities detected in ranitidine medicines.
- NDMA is classified as a probable human carcinogen based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.
- The FDA does not have scientific evidence to recommend whether individuals should continue or stop taking ranitidine medicines at this time. The agency is conducting further tests to determine the risk to consumers.
- Consumers taking OTC ranitidine may consider using other OTC products approved for their condition. To date, the FDA’s testing has not found NDMA in alternatives such as [Pepcid® AC \(famotidine\)](#), [Tagamet® \(cimetidine\)](#), [Nexium® \(esomeprazole\)](#), [Prevacid® \(lansoprazole\)](#) and [Prilosec® \(omeprazole\)](#).
- Patients taking prescription ranitidine who wish to discontinue use should talk to their health care professional about other treatment options. Multiple drugs are approved for the same or similar uses as ranitidine.
- Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using the recalled ranitidine.

- Anyone with an existing inventory of the recalled product should quarantine the product immediately.
- The FDA is continuing to test ranitidine products from multiple manufacturers and assess the possible effect on patients who have been taking ranitidine. Additionally, the FDA recently released a second testing method for manufacturers and regulators to detect and quantify NDMA in ranitidine.
- The FDA will take appropriate measures based on the results of this ongoing investigation. Some manufacturers have chosen to stop distribution of ranitidine as a precautionary measure while the FDA and other international regulators conduct their investigations of the NDMA impurity.
- The FDA continues to evaluate the safety of ranitidine and will provide more information as it becomes available.
- FDA updates regarding NDMA in ranitidine medicines can be found [here](#).
- Contact Novitium at **1-609-469-5920** and Lannett at **1-844-834-0530** for further information regarding this recall.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.